Management of HBV reactivation in non-oncological patients

References

• Yeo W, Chan PKS, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identificationof risk factors. J Med Virol. 2000;62:299–307.
   PubMed Web of Science ®Google Scholar
• Coppola N, Tonziello G, Pisaturo M, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol. 2011 Nov;83(11):1909–1916.
   PubMed Web of Science ®Google Scholar
• Sarmati L, Andreoni M, Antonelli G, et al. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper. Clin Microbiol Infect. 2017 Dec;23(12):935–940.
   PubMed Web of Science ®Google Scholar
• World Health Organization [Internet]. Geneva: World Health Organization. 2017 Jul. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/
   Google Scholar
• Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD 2018. HEPATOLOGY. 2018;67(4):1560–1599.
   Web of Science ®Google Scholar
• Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis. 2003;23:47–58.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Sagnelli C, Pisaturo M, et al. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol. 2014 Jun 28;20(24):7635–7643.
   PubMed Web of Science ®Google Scholar
• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004;11:97–107.
   PubMed Web of Science ®Google Scholar
• Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2007 Feb;45(2):507–539.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008 Feb;48(2):335–352.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370‐398.
   Web of Science ®Google Scholar
• Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2:479–486.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Pisaturo M, Martini S, et al. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol. 2014 Jun 27;6(6):384–393.
   PubMedGoogle Scholar
• Coppola N, Loquercio G, Tonziello G, et al. HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. J Clin Virol. 2013;58:315–317.
   PubMed Web of Science ®Google Scholar
• Coppola N, Onorato L, Iodice V, et al. Occult HBV infection in HCC and cirrhotic tissue of HBsAg-negative patients: a virological and clinical study. Oncotarget. 2016;7(38):62706–62714.
   PubMedGoogle Scholar
• Raimondo G, Caccamo G, Filomia R, et al. Occult HBV infection. Semin Immunopathol. 2013 Jan;35(1):39–52.
   PubMed Web of Science ®Google Scholar
• Coppola N, Onorato L, Sagnelli C, et al. Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis. Medicine (Baltimore). 2016 Jul;95(30):e4311.
   PubMed Web of Science ®Google Scholar
• Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009 May;49(5 Suppl):S156–S65.
   PubMed Web of Science ®Google Scholar
• Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397–408.
   PubMedGoogle Scholar
• Palmore TN, Shah NL, Loomba R, et al. Reactivation of Hepatitis B with reappearance of hepatitis b surface antigen after chemotherapy and immune suppression. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1130–1137.
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Lok AS, Martin P, et al. Recent US food and drug administration warnings on hepatitis b reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015 Feb;61(2):703–711.
   PubMed Web of Science ®Google Scholar
• Dai MS, Chao TY, Kao WY, et al. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol. 2004;83:769–774.
   PubMed Web of Science ®Google Scholar
• Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology. 2008;47:844–853.
   PubMed Web of Science ®Google Scholar
• Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32:3736–3743.
   PubMed Web of Science ®Google Scholar
• Ceccarelli L, Salpini R, Sarmati L, et al. Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs- positive and anti-HBc- Negative patient treated with rituximab-containing therapy. J Infect. 2012;65:180‐183.
   PubMed Web of Science ®Google Scholar
• Chew E, Thursky K, Seymour JF. Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance. Leuk Lymphoma. 2014;55:938‐939.
   PubMed Web of Science ®Google Scholar
• Tonziello G, Pisaturo M, Sica A, et al. Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection. 2013;41(1):225–229.
   PubMed Web of Science ®Google Scholar
• Macera M, Capoluongo N, Gambardella M, et al. The reactivation of occult HBV infection emerging with the case of acute hepatitis B in the wife of a subject treated with rituximab-based chemotherapy. Antivir Ther. 2015;20(3):349–352.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–611.
   PubMed Web of Science ®Google Scholar
• Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–220.
   PubMed Web of Science ®Google Scholar
• Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn’s and Colitis. 2017 June 1;11(6):649–670. [cited 2017 Feb 02].
   PubMed Web of Science ®Google Scholar
• 3rd european evidence-based consensus on the diagnosis and management of Crohn’s Disease 2016: part 1: diagnosis and medical management. Journal of Crohn’s and Colitis. 2017 Jan 1;11(1):3–25. [Cited 2016 Sept 22].
   PubMed Web of Science ®Google Scholar
• Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab. J Gastroenterol. 2008;43(5):397–401.
   PubMed Web of Science ®Google Scholar
• Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut. 2004;53:1363e5.
   Web of Science ®Google Scholar
• Loras C, Gisbert JP, Minguez M, et al. for the REPENTINA study, GETECCU (Grupo Espa ̃nol de enfermedades de crohn y colitis ulcerosa) group liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010;59:1340e1346.
   Web of Science ®Google Scholar
• Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, et al., BIOGEAS Study Group. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90:359–371.
   PubMed Web of Science ®Google Scholar
• Morisco F, Castiglione F, Rispo A, et al. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. J Viral Hepat. 2013 Mar;20(3):200–208.
   PubMed Web of Science ®Google Scholar
• Madonia S, Orlando A, Scimeca D, et al. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007 Apr;13(4):508–509.
   PubMed Web of Science ®Google Scholar
• Miyake Y, Hasebe A, Tanihira T, et al. Hepatitis B virus reactivation induced by infliximab administration in a patient with Crohn’s Disease. Hindawi Publishing Corporation Case Reports in Hepatology. 2013 Article ID 461879. 4.
   Google Scholar
• Zeitz J, Mullhaupt B, Fruehauf H, et al. Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology. 2009;50:653–654.
   PubMed Web of Science ®Google Scholar
• Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohn’s disease: need for HBV-screening? World J Gastroenterol. 2006 Feb 14;12(6):974–976. .
   PubMed Web of Science ®Google Scholar
• Loras C, Gisbert JP, Saro MC, et al. REPENTINA study, GETECCU group (Grupo Español de trabajo de Enfermedades de Crohn y Colitis Ulcerosa)., Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3). J Crohns Colitis. 2014 Nov;8(11):1529–1538.
   PubMed Web of Science ®Google Scholar
• Papa A, Felice C, Marzo M, et al. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents. J Crohns Colitis. 2013 Mar;7(2):113–119.
   PubMed Web of Science ®Google Scholar
• Purnak S, Purnak T. Hepatitis B virus reactivation after ustekinumab treatment. Br J Dermatol. 2014;170:477–478.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Beavers KL, Hammond SP, et al. American gastroenterological association institute. american gastroenterological association institute guideline on the prevention treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215‐219.
   Web of Science ®Google Scholar
• Bonifati C, Lora V, Graceffa D, et al. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016 Jul 28;22(28):6444–6455.
   PubMed Web of Science ®Google Scholar
• Chiu HY, Chen CH, Wu MS, et al. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013 Dec;169(6):1295–1303.
   PubMed Web of Science ®Google Scholar
• Koskinas J, Tampaki M, Doumba PP, et al. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient. Br J Dermatol. 2013;168:679–680.
   PubMed Web of Science ®Google Scholar
• Sanz-Bueno J, Vanaclocha F, Garcia-Doval I, et al. Risk of reactivation of hepatitis B virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM database. Actas Dermosifiliogr. 2015;106:477–482.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Dapavo P, Conti A, et al. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1853–1859.
   PubMed Web of Science ®Google Scholar
• Cantini F, Boccia S, Goletti D, et al. HBV Reactivation in patients treated with antitumor necrosis factor-alpha (TNF-α) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis. Int J Rheumatol. 2014;2014:926836.
   PubMedGoogle Scholar
• Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am AcadDermatol. 2017 Jul;77(1):88–97.e5.
   PubMed Web of Science ®Google Scholar
• Moghoofei M, Mostafaei S, Ashraf-Ganjouei A, et al. HBV reactivation in rheumatic diseases patients under therapy: a meta-analysis. Microb Pathog. 2018;114:436–443.
   PubMed Web of Science ®Google Scholar
• De Nard F, Todoerti M, Grosso V, et al. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: extending perspective from old to newer drugs. World J Hepatol. 2015;7(3):344–361.
   PubMed Web of Science ®Google Scholar
• Flowers MA, Heathcote J, Wanless IR, et al. Fulminant hepatitis as a consequence of reactivation ofhepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med. 1990;112:381–382.
   PubMed Web of Science ®Google Scholar
• Hagiyama H, Kubota T, Komano Y, et al. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2004;22:375–376.
   PubMed Web of Science ®Google Scholar
• Ito S, Nakazono K, Murasawa A, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum. 2001;44:339–342.
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Ishikawa M, Nakauchi M, et al. Antibody to hepatitis B e positive hepatitis induced by withdrawal of steroid therapy for polymyositis: response to interferon-alpha and cyclosporin A. Intern Med. 1998;37:519–522.
   PubMed Web of Science ®Google Scholar
• Narvaez J, Rodriguez-Moreno J, Martinez-Aguila MD, et al. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol. 1998;25:2037–2038.
   PubMed Web of Science ®Google Scholar
• Laohapand C, Arromdee E, Tanwandee T. Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients. Hepatol Int. 2015 Apr 9;9(2):202–208. Epub 2015 Jan 15.
   PubMed Web of Science ®Google Scholar
• Navarro-Millan I, Curtis JR. Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factors biologics for rheumatoid arthritis. Curr Opin Rheumatol. 2013;25:384–390.
   PubMed Web of Science ®Google Scholar
• Chen MH, Chen MH, Liu CY, et al. Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. J Infect Dis. 2017;215(4):566–573.
   PubMed Web of Science ®Google Scholar
• Ryu HH, Lee EY, Shin K, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012;31(6):931–936.
   PubMed Web of Science ®Google Scholar
• Chung SJ, Kim JK, Park MC, et al. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2009;36:2416–2420.
   PubMed Web of Science ®Google Scholar
• Zingarelli S, Frassi M, Bazzani C, et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports 3 cases and review of the literature. J Rheumatol. 2009;36:1188e94.
   Web of Science ®Google Scholar
• Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumor necrosis factor alpha therapy. Ann Rheum Dis. 2011;70:1719e25.
   Web of Science ®Google Scholar
• Mitroulis I, Hatzara C, Kandili A, et al. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2013;72(2):308.
   PubMed Web of Science ®Google Scholar
• Tamori A, Koike T, Goto H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negativecohorts. J Gastroenterol. 2011;46(4):556–564.
   PubMed Web of Science ®Google Scholar
• Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumour necrosis factor therapy. Clin Exp Rheumatol. 2013;31(1):118–121.
   PubMed Web of Science ®Google Scholar
• Lee YH, Bae SC, Song GG. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. Int J Rheum Dis. 2013;16(5):527–531.
   PubMed Web of Science ®Google Scholar
• Fukuda W, Hanyu T, Katayama M, et al. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis. 2017;76(6):1051–1056.
   PubMed Web of Science ®Google Scholar
• Varisco V, Viganò M, Batticciotto A, et al. Low risk of hepatitis B virus reactivation in HBsAg-negative/Anti-HBc− positive carriers receiving rituximab for rheumatoid arthritis: a retrospective multicenter Italian study. J Rheumatol. 2016;43(5):869–874.
   PubMed Web of Science ®Google Scholar
• Urata Y, Uesato R, Tanaka D, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011;21(1):16–23.
   PubMed Web of Science ®Google Scholar
• Nakamura J, Nagashima T, Nagatani K, et al. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2016;19(5):470–475.
   PubMed Web of Science ®Google Scholar
• Morisco F, Guarino M, La Bella S, et al. Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. BMC Gastroenterol. 2014;19(14):214.
   Web of Science ®Google Scholar
• Chen YM, Yang SS, Chen DY. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: a narrative review. J Microbiol Immunol Infect. 2017;S1684–1182(17):30234–30237.
   Google Scholar
• Perrillo RP, Gish R, Falck-Ytter YT. American gastroenterological association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221–244.e3.
   PubMed Web of Science ®Google Scholar
• Wootla B, Watzlawik JO, Stavropoulos N, et al. Recent advances in monoclonal antibody therapies for multiple sclerosis. Expert Opin Biol Ther. 2016;16(6):827–839.
   PubMed Web of Science ®Google Scholar
• Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742–1749.
   PubMed Web of Science ®Google Scholar
• Hsu C, Hsiung CA, Su I-J, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology. 2008;47:844–853.
   PubMed Web of Science ®Google Scholar
• Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–528.
   PubMed Web of Science ®Google Scholar
• Katz LH, Fraser A, Gafter-Gvili A, et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat. 2008;15:89–102.
   PubMed Web of Science ®Google Scholar
• Francisci D, Falcinelli F, Schiaroli E, et al. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection. 2010;38:58–61.
   PubMed Web of Science ®Google Scholar
• Brost S, Schnitzler P, Stremmel W, et al. Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. World J Gastroenterol. 2010 Nov;21(16):5447‐5451.
   Google Scholar
• Chen FW, Coyle L, Jones BE, et al. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease. Liver Int. 2013;33:1203‐1210.
   Web of Science ®Google Scholar
• Koskinas JS, Deutsch M, Adamidi S, et al. The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center. Eur J Intern Med. 2014;25:768‐771.
   PubMed Web of Science ®Google Scholar
• Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31:2765–2772.
   PubMed Web of Science ®Google Scholar
• Buti M, Manzano ML, Morillas RM. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: the Preblin study. PLoS One. 2017 Sep;12(12):e0184550.
   PubMedGoogle Scholar
• Crisp RL, Solari L, Vota D, et al. A prospective study to assess the predictive value for hereditary spherocytosis using five laboratory tests (cryohemolysis test, eosin-5’-maleimide flow cytometry, osmotic fragility test, autohemolysis test, and SDS-PAGE) on 50 hereditary spherocytosis families in Argentina. Ann Hematol. 2011;90:625–634.
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA. 2015;313:1617‐1618.
   PubMed Web of Science ®Google Scholar
• Fukushima N, Mizuta T, Tanaka M, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol. 2009;20:2013‐2017.
   Web of Science ®Google Scholar
• Marrone A, Capoluongo N, D’Amore C, et al. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy. J Viral Hepat. 2018 Feb;25(2):198–204.
   PubMed Web of Science ®Google Scholar
• Viganò M, Serra G, Casella G, et al. Reactivation of hepatitis B virus during targeted therapies for cancer and immunemediated disorders. Expert Opin Biol Ther. 2016;16:917–926.
   PubMed Web of Science ®Google Scholar
• Grossi G, Viganò M, Facchetti F, et al. Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports. Haematologica. 2017;102:e423–e426.
   PubMedGoogle Scholar
• Grossi G, Loglio A, Viganò M, et al. Universal prophylaxis with lamivudine prevents hepatitis B reactivation in HBsAg-negative/anti-HBC positive patients undergoing rituximab-based chemotherapy for non-Hodgkin b cell lymphoma – final results. Hepatology. 2016;64:88A.
   Web of Science ®Google Scholar
• Cerva C, Colagrossi L, Maffongelli G, et al. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc positive or HBV-negative recipients with an anti-HBc-positive donor. Clin Microbiol Infect. 2016;22:946.e1–946.e8.
   PubMed Web of Science ®Google Scholar
• Mozessohn L, Chan KK, Feld JJ, et al. Hepatitis B reactivation in HBsAg negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat. 2015;22:842–849.
   PubMed Web of Science ®Google Scholar